Mersana Therapeutics, Inc.·4

Mar 14, 4:49 PM ET

Spellman David A 4

4 · Mersana Therapeutics, Inc. · Filed Mar 14, 2018

Insider Transaction Report

Form 4
Period: 2018-03-12
Spellman David A
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2018-03-12+150,000150,000 total
    Exercise: $13.97Exp: 2021-03-12Common Stock (150,000 underlying)
Footnotes (1)
  • [F1]The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years.

Documents

1 file
  • 4
    a4.xmlPrimary

    4